GWM Advisors LLC Acquires New Position in Regeneron Pharmaceuticals Inc (REGN)

GWM Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in the 1st quarter, HoldingsChannel reports. The fund acquired 59,835 shares of the biopharmaceutical company’s stock, valued at approximately $124,000.

Several other large investors have also recently modified their holdings of REGN. Martingale Asset Management L P bought a new position in Regeneron Pharmaceuticals in the first quarter worth about $536,000. Rational Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 21,137.5% in the first quarter. Rational Advisors LLC now owns 5,097 shares of the biopharmaceutical company’s stock worth $2,093,000 after purchasing an additional 5,073 shares during the period. Piedmont Investment Advisors Inc. grew its holdings in Regeneron Pharmaceuticals by 70.6% in the first quarter. Piedmont Investment Advisors Inc. now owns 17,609 shares of the biopharmaceutical company’s stock worth $7,231,000 after purchasing an additional 7,290 shares during the period. Catalyst Capital Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the first quarter worth about $41,000. Finally, Barings LLC grew its holdings in Regeneron Pharmaceuticals by 137.8% in the first quarter. Barings LLC now owns 4,107 shares of the biopharmaceutical company’s stock worth $1,686,000 after purchasing an additional 2,380 shares during the period. 67.61% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total value of $305,930.00. Following the sale, the director now owns 11,323 shares in the company, valued at $3,464,045.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Sanofi sold 131,115 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $412.17, for a total transaction of $54,041,669.55. The disclosure for this sale can be found here. In the last quarter, insiders have sold 141,968 shares of company stock worth $57,360,056. Corporate insiders own 11.84% of the company’s stock.

NASDAQ:REGN opened at $312.56 on Friday. Regeneron Pharmaceuticals Inc has a 52 week low of $291.69 and a 52 week high of $442.00. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.78 and a current ratio of 4.58. The company has a market cap of $34.16 billion, a PE ratio of 15.79, a PEG ratio of 1.46 and a beta of 1.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 EPS for the quarter, missing the Zacks’ consensus estimate of $5.24 by ($0.79). Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The firm had revenue of $1.71 billion for the quarter, compared to analysts’ expectations of $1.76 billion. During the same quarter in the previous year, the company earned $4.67 EPS. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. As a group, equities analysts predict that Regeneron Pharmaceuticals Inc will post 18.37 earnings per share for the current fiscal year.

REGN has been the topic of a number of recent research reports. Guggenheim cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $466.00 to $425.00 in a report on Friday, February 22nd. Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 price objective on the stock in a report on Thursday, February 7th. BidaskClub cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 7th. Piper Jaffray Companies restated an “overweight” rating and issued a $435.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 7th. Finally, ValuEngine upgraded shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $397.44.

ILLEGAL ACTIVITY WARNING: This article was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/25/gwm-advisors-llc-acquires-new-position-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: What is the Fibonacci sequence?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.